AnGes MG Inc.
Senri Life Science Center Building 10F
1-4-2
Shinsenri Higashi-machi
Toyonaka
560-0082
Tel: 03-5730-2480
Website: http://www.anges-mg.com/en/index.html
Email: info@anges-mg.com
18 articles about AnGes MG Inc.
-
BioSpace Global Roundup, Sept. 10
9/10/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics
1/15/2020
Emendo Biotherapeutics announced a Series B investment totaling $61 million led by AnGes, Inc., a Japan-based biopharma, reflecting its strategic interest in partnering with Emendo on the development of specific indications.
-
AnGes Terminates Phase III HGF Plasmid, Starts New Plan
6/27/2016
-
AnGes MG Inc. Starts Global Phase 3 Clinical Trials Of Collategene® For Critical Limb Ischemia
10/6/2014
-
AnGes MG Inc. Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma Corporation for Exclusive Marketing Rights of Collategene® in the United States
10/24/2012
-
Vical Incorporated and AnGes MG Inc. Sign Letter of Intent for Pandemic Influenza Program
10/9/2008
-
Vical Incorporated and AnGes MG Inc. Sign Letter of Intent for Pandemic Influenza Program
10/8/2008
-
Vical Incorporated Receives $1 Million Milestone Payment From AnGes MG Inc. for Angiogenesis Program
7/22/2008
-
AnGes MG Inc. Files NDA in Japan for Collategene Angiogenesis Product
3/28/2008
-
Vical Incorporated Receives Payment from AnGes MG Inc. for Allovectin-7(R) Phase 3 Pivotal Trial
1/17/2008
-
AnGes MG Inc. Submits BLA to Japanese Ministry of Health
8/13/2007
-
Vical Incorporated Licensee AnGes MG Inc. Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
6/18/2007
-
AnGes MG Inc., Vical Incorporated To Start Phase III Clinical Trial Of Allovectin For Gene Therapy
1/17/2007
-
Vical Incorporated Announces News Release And Conference Call Schedule To Discuss Collaborative Agreement With AnGes MG Inc. For Allovectin-7(R)
5/30/2006
-
Vical Incorporated And AnGes MG Inc. Sign $100M Deal; To Collaborate On Allovectin-7(R) And Begin Phase 3 Pivotal Trial
5/30/2006
-
AnGes MG Inc. Announces Results Of Phase I Clinical Trial Of HGF Gene Medicine
5/12/2006
-
AnGes MG Inc. And Seikagaku To Dissolve Joint Development Agreement For NFkB Decoy-Oligo-Based Intraarticular Injection
2/6/2006
-
AnGes MG Inc. And FALCO Biosystems To Form Business Alliance In Gene Therapy Business
11/30/2005